Essay on protecting the Orphan Drug Act by NORD’s Peter L. Saltonstall published in CQ Researcher

Categorized in -


An essay by NORD President and CEO Peter L. Saltonstall on the Orphan Drug Act is featured in Congressional Quarterly Researcher’s Conquering Rare Diseases special issue.

“Rare disease patients cannot afford to return to the early 1980s. The more than 25 million rare disease patients in the United States are counting on Congress to ensure that the success of the ODA endures. We should not reverse course. Rather, given the unmet need that remains, we should redouble our efforts.”

Read the essay in its entirety here (subscription required):